These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 6190925)

  • 1. Liposomes as a tool to study the role of membrane presentation in the immunogenicity of a MuLV-related tumor antigen.
    Gerlier D; Bakouche O; Dore JF
    J Immunol; 1983 Jul; 131(1):485-90. PubMed ID: 6190925
    [No Abstract]   [Full Text] [Related]  

  • 2. Protection against radiation leukemogenesis by repeated injections of immune and nonimmune foreign sera.
    Ferrer JF; Lieberman M; Kaplan HS
    Cancer Res; 1973 Jun; 33(6):1339-43. PubMed ID: 4352370
    [No Abstract]   [Full Text] [Related]  

  • 3. Amplified expression of murine leukemia virus (MuLV)-coded antigens on thymocytes and leukemia cells of AKR mice after infection by dualtropic (MCF) MuLV.
    O'Donnell PV; Nowinski RC; Stockert E
    Virology; 1982 Jun; 119(2):450-64. PubMed ID: 6177096
    [No Abstract]   [Full Text] [Related]  

  • 4. New immunological approaches to the application of BCG vaccine for the treatments of tumors (acute leukoses).
    Ter-Grigorov VS; Yablokova TB; Levy DT; Rosenberg AM; Pisarenko NN; Levewbook IS; Graff IA
    J Hyg Epidemiol Microbiol Immunol; 1976; 20(1):25-31. PubMed ID: 57195
    [No Abstract]   [Full Text] [Related]  

  • 5. H-2-restricted cytolytic T lymphocytes specific for a subclass of AKR endogenous leukemia virus-induced tumors: correlation of tumor cell susceptibility with expression of the gross cell surface antigen.
    Green WR
    J Immunol; 1980 Dec; 125(6):2584-90. PubMed ID: 6159413
    [No Abstract]   [Full Text] [Related]  

  • 6. Presentation of an MuLV-related tumour antigen in liposomes as a potent tertiary immunogen after adoptive transfer.
    Bakouche O; Gerlier D
    Immunology; 1986 Feb; 57(2):219-23. PubMed ID: 3949369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological analysis of cell surface antigens of tumors induced by murine leukemia virus.
    Herberman RB
    J Natl Cancer Inst; 1972 Jan; 48(1):265-71. PubMed ID: 4119883
    [No Abstract]   [Full Text] [Related]  

  • 8. Production of migration inhibition factor by spleen cells of normal rats upon culture in vitro with tumor cells and cells expressing endogenous virus.
    Sharma JM; Herberman RB; Djeu JY; Nunn ME
    J Immunol; 1979 Jul; 123(1):222-31. PubMed ID: 221590
    [No Abstract]   [Full Text] [Related]  

  • 9. Specificity of cytolytic T cells directed against AKR/Gross virus-induced syngeneic leukemias: antibodies directed against H-2K, but not against viral proteins, inhibit lysis.
    Green WR; Nowinski RC; Henney CS
    J Immunol; 1980 Aug; 125(2):647-55. PubMed ID: 6156211
    [No Abstract]   [Full Text] [Related]  

  • 10. Genes of the H-2 complex regulate the antibody response to murine leukemia virus.
    Vlug A; Schoenmakers HJ; Melief CJ
    J Immunol; 1981 Jun; 126(6):2355-60. PubMed ID: 6262410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of antibody response to liposome-associated Gross-virus cell-surface antigen (GCSAa).
    Gerlier D; Sakai F; Doré JF
    Br J Cancer; 1980 Feb; 41(2):236-42. PubMed ID: 7370163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition.
    Bakouche O; Gerlier D
    Immunology; 1986 Jul; 58(3):507-13. PubMed ID: 3733150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-surface and virion-envelope antigens shared by radiation leukemia virus (RadLV) and other murine c-type viruses.
    Ferrer JF
    Int J Cancer; 1973 Sep; 12(2):378-88. PubMed ID: 4134124
    [No Abstract]   [Full Text] [Related]  

  • 14. The structural proteins of murine leukemia virus and the pathogenesis of necrotizing arteritis and glomerulonephritis in SL/Ni mice.
    Yoshiki T; Hayasaka T; Fukatsu R; Shirai T; Itoh T; Ikeda H; Katagiri M
    J Immunol; 1979 May; 122(5):1812-20. PubMed ID: 221579
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancement of lymphoma cell immunogenicity by infection with nononcogenic virus.
    Eaton MD; Heller JA; Scala AR
    Cancer Res; 1973 Dec; 33(12):3293-8. PubMed ID: 4357358
    [No Abstract]   [Full Text] [Related]  

  • 16. Antigenic modulation as a mechanism for tumor escape from immune destruction: identification of modulation-positive and modulation-negative mouse lymphomas with xenoantisera to murine leukemia virus gp70.
    Stackpole CW; Cremona P; Leonard C; Stremmel P
    J Immunol; 1980 Oct; 125(4):1715-23. PubMed ID: 6251136
    [No Abstract]   [Full Text] [Related]  

  • 17. Murine leukemia virus-associated cell surface antigens in rats neonatally infected with Gross murine leukemia virus.
    Basch RS; Grausz D; Harris N; Mitchison NA
    J Natl Cancer Inst; 1979 Dec; 63(6):1485-92. PubMed ID: 292817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the susceptibility of C57BL-6 mice to Rauscher virus. 3. Kinetics of humoral antibody response to cell-surface antigens in neonatally inoculated mice.
    Ishimoto A; Ito Y
    J Natl Cancer Inst; 1973 Aug; 51(2):553-64. PubMed ID: 4765372
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular analysis of the cytolytic T-lymphocyte response elicited by retrovirus-induced tumours in mice.
    Plata F; Langlade-Demoyen P; Abastado JP; Berbar T; Kourilsky P
    Ann Inst Pasteur Immunol; 1986; 137D(3):409-12. PubMed ID: 3493789
    [No Abstract]   [Full Text] [Related]  

  • 20. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
    Green WR
    J Immunol; 1983 Dec; 131(6):3078-84. PubMed ID: 6605998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.